Idenix Pharmaceuticals Inc.'s FDA-ordered clinical hold on the nucleoside inhibitor valopicitabine for hepatitis C virus comes just a month after encouraging Phase II data, and probably means death for the drug also known as NM283, thanks to gastrointestinal side effects that the agency found serious enough to stop development. (BioWorld Today) Read More